SynopsisSun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. Significant progress is being made on the acquisition of Organon, with completion targeted for the last quarter of FY2027. This strategic move is set to enhance Sun Pharma's global presence and product portfolio across key therapeutic areas.Listen to this article in summarized formatReutersSun Pharma logo Mumbai: India's largest drug maker, Sun Pharma, has guided a high single-digit consolidated topline growth for FY2027 and research spending of 6%-7% of total sales for next year.Speaking on a call Friday evening with sector analysts following the announcement of its FY2026 and fourth-quarter earnings, Dilip Shanghvi, executive chairman, Sun Pharma, said the guidance is based on the current understanding of the regulatory and macro environment.Also Read: ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateOn the next steps for Organon, a company that Sun Pharma acquired last month for a record $11.75 billion, Shanghvi noted that the company has set up an Integration Management Office and initiated activities, including regulatory filings in various markets. He added that the acquisition of Organon is expected to be completed by the last quarter of FY2027.In a presentation, Sun Pharma said it is assessing the combined capabilities and plans for cultural assimilation.Earlier, Sun Pharma reported sales of ₹14,559.8 crore for the fourth quarter of FY2026, a year-on-year increase of 13.6%. Sun Pharma's net profit rose 26.2% to ₹2,714 crore over the same period.Co expects FY27 sales to grow in high single digits and to complete Organon acquisition by end of the fiscal yearThe company closed the full year of FY2026 with sales of ₹58,220 crore, a growth of 11.9%, with Ebitda of ₹17,731.4 crore, up 16%. The Ebitda margin stood at 30.3%.The growth came on the back of strong growth in India, where Sun Pharma holds 8.4% of the total market share, the highest in the industry, along with continuing traction in the global innovative medicines business, which includes products like Ilumya (plaque psoriasis), Odomzo (anti-cancer drug), Unloxcyt (anti-cancer), Winlevi (dermatology), and Leqselvi (hair loss treatment).Kirti Ganorkar, managing director, Sun Pharma, told analysts that the Organon acquisition is expected to be complementary for Sun Pharma, specifically in four areas-biosimilars; established brands, which he said account for half of Organon's sales (roughly $6.2 billion); and the women's health business, which adds to the Indian company's innovative products portfolio across dermatology, ophthalmology, and oncology."There are hardly any product overlaps," Ganorkar added.Also Read: Sun Pharma explores funding mix for $12 billion Organon deal"The Organon acquisition is expected to further accelerate Sun Pharma's transformation into a leading global pharmaceutical company," Ganorkar noted in a separate release.Sun Pharma proposed a final dividend of ₹5 per share, taking the total FY2026 dividend to ₹16 per share.Read More News on...moreless